E German Pharma Firm Seeks New Markets In West

17 February 1997

Eastern German pharmaceuticals company Serum-Werk Bernburg AG, based inSaxony-Anhalt, is using a low-price strategy to expand its distribution network on the western German market with synthesis and infusion solution products, said SWB chairman Helge Faenger when he opened a new plant for hydroxyethyl starch.

This product, until now imported from Puerto Rico, will be used as a plasma expander in accident and emergency medicine and in hospitals. SWB was eastern Germany's largest producer of infusion solutions in the period of communist government and it now has market share of around 40% compared with only 5% in western Germany. The company was privatized in 1992 in a management buy-out. Sales and profits in 1997 are expected to stabilize at around the 1996 level of 49 million Deutchemarks ($29.9 million) with profits at 3.5 million marks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight